Related Experiment Video
Updated: May 29, 2026
09:03
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
[Fatty liver and hepatitis C virus infection]
Marianna Lakatos1, Krisztina Hagymási, Gabriella Lengyel
1Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
Orvosi Hetilap
|September 8, 2011
Summary
Hepatitis C virus (HCV) infection often causes fatty liver disease (steatosis). This review explores how steatosis and insulin resistance impact HCV treatment effectiveness.
Area of Science:
- Hepatology
- Virology
- Metabolic Syndrome
Context:
- Hepatitis C virus (HCV) infection is a global health concern, frequently leading to liver conditions like steatosis, cirrhosis, and hepatocellular carcinoma.
- Approximately 55% of individuals with chronic HCV infection develop steatosis, a condition influenced by both viral and metabolic factors.
- HCV proteins interact with cellular pathways, but the precise mechanisms driving steatosis require further investigation.
Purpose:
- To review the complex interplay between Hepatitis C virus infection, hepatic steatosis, and insulin resistance.
- To elucidate how these factors influence the efficacy of antiviral therapies for chronic Hepatitis C.
- To highlight the need for further research into the molecular mechanisms linking HCV, steatosis, and metabolic dysfunction.
Summary:
- Hepatitis C virus infection is a significant cause of liver disease globally, with steatosis (fatty liver) affecting over half of chronic cases.
- Steatosis development in HCV infection results from a combination of viral actions on cellular pathways and metabolic factors like obesity and insulin resistance.
- Insulin resistance and steatosis may contribute to viral resistance against antiviral treatments, complicating disease management.
Impact:
- Provides a comprehensive overview of the relationship between steatosis, insulin resistance, and antiviral treatment response in Hepatitis C.
- Identifies key areas for future research into the pathogenesis of HCV-associated fatty liver disease.
- Informs clinical strategies for managing chronic Hepatitis C, particularly in patients with metabolic comorbidities.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...